Chronic kidney disease (CKD) is an inherently systemic disease that refers to a long-term
loss of kidney function. The progression of CKD has repercussions for other organs, leading …

The causes of excess cardiovascular mortality associated with chronic kidney disease
(CKD) have been attributed in part to the CKD-mineral bone disorder syndrome (CKD-MBD) …

In addition to its structural role, the skeleton serves as an endocrine organ that controls
mineral metabolism and energy homeostasis. Three major cell types in bone-osteoblasts …

Sclerostin has traditionally been thought of as a local inhibitor of bone acquisition that
antagonizes the profound osteoanabolic capacity of activated Wnt/β-catenin signaling, but …

Over the last 15 years several biological markers of bone turnover have been developed
with increased specificity and sensitivity. In osteoporosis clinical studies, the IOF and IFCC …

Background Osteoprotegerin (OPG), sclerostin and DKK1 constitute opposite bone turnover
inhibitors, OPG inhibiting osteoclastogenesis while sclerostin and DKK1 exerting their …

For more than a decade, the Wnt–β-catenin pathway has been the focus of intense basic
and clinical research in the bone field because of its importance in skeletal development …

Sclerostin, an osteocyte-derived inhibitor of bone formation, is linked to mineral bone
disorder. In order to validate its potential as a predictor of vascular calcification, we explored …

Background: The chronic kidney disease (CKD)-mineral and bone disorder (MBD)
syndrome is an important contributor to the CKD-associated cardiovascular disease and …

Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality,
leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in …